PL3766885T3 - Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy - Google Patents
Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazyInfo
- Publication number
- PL3766885T3 PL3766885T3 PL20193125.0T PL20193125T PL3766885T3 PL 3766885 T3 PL3766885 T3 PL 3766885T3 PL 20193125 T PL20193125 T PL 20193125T PL 3766885 T3 PL3766885 T3 PL 3766885T3
- Authority
- PL
- Poland
- Prior art keywords
- phosphodiesterase inhibitors
- tricyclic compounds
- tricyclic
- compounds
- phosphodiesterase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562180815P | 2015-06-17 | 2015-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3766885T3 true PL3766885T3 (pl) | 2022-09-19 |
Family
ID=56418558
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16739563T PL3310784T3 (pl) | 2015-06-17 | 2016-06-09 | Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy |
PL20193125.0T PL3766885T3 (pl) | 2015-06-17 | 2016-06-09 | Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16739563T PL3310784T3 (pl) | 2015-06-17 | 2016-06-09 | Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy |
Country Status (29)
Country | Link |
---|---|
US (3) | US11472805B2 (pl) |
EP (2) | EP3310784B1 (pl) |
JP (1) | JP6827959B2 (pl) |
KR (2) | KR20180004817A (pl) |
CN (1) | CN107787322B (pl) |
AU (2) | AU2016280137B2 (pl) |
BR (1) | BR112017026191B1 (pl) |
CA (1) | CA2989456C (pl) |
CO (1) | CO2017012994A2 (pl) |
CR (1) | CR20170572A (pl) |
CU (1) | CU20170153A7 (pl) |
DK (2) | DK3766885T3 (pl) |
DO (1) | DOP2017000297A (pl) |
EA (1) | EA039714B1 (pl) |
EC (1) | ECSP18003372A (pl) |
ES (2) | ES2832893T3 (pl) |
HK (2) | HK1245790A1 (pl) |
HU (2) | HUE051898T2 (pl) |
IL (1) | IL255444B (pl) |
MX (1) | MX2017016149A (pl) |
PE (1) | PE20180478A1 (pl) |
PH (1) | PH12017502260A1 (pl) |
PL (2) | PL3310784T3 (pl) |
PT (2) | PT3766885T (pl) |
SG (1) | SG10201912333PA (pl) |
TN (1) | TN2017000485A1 (pl) |
TW (1) | TWI623538B (pl) |
UA (1) | UA125334C2 (pl) |
WO (1) | WO2016203347A1 (pl) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TN2017000485A1 (en) * | 2015-06-17 | 2019-04-12 | Pfizer | Tricyclic compounds and their use as phosphodiesterase inhibitors |
CN109438448B (zh) * | 2018-11-07 | 2021-08-27 | 成都大学 | 一种吲哚并七元环化合物及其制备方法和用途 |
JP2022518292A (ja) * | 2019-01-23 | 2022-03-14 | パス セラピューティクス,インク. | ホスホジエステラーゼ4(pde4)阻害によるてんかんの治療方法 |
US20240009195A1 (en) * | 2020-07-26 | 2024-01-11 | Intra-Cellular Therapies, Inc. | Novel uses |
WO2023076547A1 (en) * | 2021-10-29 | 2023-05-04 | Sensorium Therapeutics, Inc. | Deuterated forms of alkaloid compounds and therapeutic uses thereof |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1965981C3 (de) * | 1968-02-13 | 1978-08-31 | Sumitomo Chemical Co., Ltd., Osaka (Japan) | 9-Phenyl-lO-oxopiperazino [l,2-a]-indole und Verfahren zu ihrer Herstellung |
DE2005845A1 (de) | 1969-02-12 | 1970-09-03 | Sumitomo Chemical Company, Ltd., Osaka (Japan) | Verfahren zur Herstellung von Benzodiazepinen und ihren Salzen |
CH560201A5 (en) | 1969-03-11 | 1975-03-27 | Hoffmann La Roche | 1 4-benzodiazepin derivs anti-convulsive, - muscle relaxant, tranquillising |
AT299964B (de) * | 1969-04-14 | 1972-07-10 | Sumitomo Chemical Co | Verfahren zur Herstellung neuer [2-(Dioxo-piperazino)-benzoyl]-pyridinderivate bzw. von Salzen hievon |
DE2144272A1 (en) * | 1971-09-03 | 1972-03-23 | Sumitomo Chemical Co Ltd , Osaka (Japan) | Nitro-benzodiazepines - prepn from 2-(2,3-diketopiperazino) nitrobenzophenones |
US4022778A (en) * | 1971-11-05 | 1977-05-10 | American Home Products Corporation | 10-Aryl-1,2,3,4-tetrahydropyrazino(1,2-α)indole and derivatives thereof |
JPS5033259B2 (pl) * | 1972-03-31 | 1975-10-29 | ||
EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
EP0683234B2 (en) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
SI0994728T1 (sl) | 1997-04-09 | 2009-02-28 | Intellect Neurosciences Inc | Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo |
US6929808B2 (en) | 2000-11-03 | 2005-08-16 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
EP1094816B1 (en) | 1998-07-06 | 2008-12-10 | Bristol-Myers Squibb Company | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
IT1313593B1 (it) | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo. |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
IL151378A0 (en) | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
CA2417106C (en) | 2000-07-31 | 2007-09-18 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
ATE358481T1 (de) | 2001-02-28 | 2007-04-15 | Merck & Co Inc | Acylierte piperidinderivate als melanocortin-4- rezeptoragonisten |
EP1406631A4 (en) | 2001-06-13 | 2005-03-23 | Univ Michigan | DOPAMINE RECEPTOR LIGANDS AND CORRESPONDING THERAPEUTIC METHODS |
EP1285922A1 (en) * | 2001-08-13 | 2003-02-26 | Warner-Lambert Company | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
FR2832711B1 (fr) * | 2001-11-26 | 2004-01-30 | Warner Lambert Co | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
ES2246481T3 (es) | 2002-02-27 | 2006-02-16 | Pfizer Products Inc. | Inhibidores de la acc. |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
AU2003279216A1 (en) | 2002-10-09 | 2004-05-04 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
FR2853329B1 (fr) | 2003-04-02 | 2006-07-14 | Onera (Off Nat Aerospatiale) | Procede pour former sur un metal un revetement protecteur contenant de l'aluminium et du zirconium |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
WO2004110996A1 (en) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
EP1720847A1 (en) | 2004-02-02 | 2006-11-15 | Pfizer Products Incorporated | Histamine-3 receptor modulators |
RU2266906C1 (ru) | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
ITMI20040874A1 (it) * | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
NZ550229A (en) | 2004-05-12 | 2009-07-31 | Pfizer Prod Inc | Proline derivatives and their use as dipeptidyl peptidase IV inhibitors |
CN1950374A (zh) | 2004-05-25 | 2007-04-18 | 辉瑞产品公司 | 四氮杂苯并[e]甘菊环衍生物及其类似物 |
TWI355389B (en) | 2004-07-30 | 2012-01-01 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide a |
GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
EP1827493A4 (en) | 2004-12-22 | 2009-09-30 | Univ St Louis | USE OF ANTI-ABETA ANTIBODIES FOR TREATING TRAUMATIC BRAIN INJURY |
AU2006204522A1 (en) | 2005-01-03 | 2006-07-13 | Universita Degli Studi Di Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
EP1881985B1 (en) | 2005-05-12 | 2010-12-29 | Pfizer, Inc. | Anhydrous crystalline forms of n-ý1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl¨methanesulfonamide |
WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
CA2607499C (en) | 2005-06-22 | 2010-11-30 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
EP1779849A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of septic shock |
EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
EP2007749A2 (en) | 2006-03-13 | 2008-12-31 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
PT2463283E (pt) | 2006-04-20 | 2014-08-27 | Pfizer Prod Inc | Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase |
RS20080484A (en) | 2006-04-21 | 2009-07-15 | Pfizer Products Inc., | PYRIDINE[3,4-b] PYRAZINONES |
WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
US20090270435A1 (en) | 2006-11-29 | 2009-10-29 | Jeffrey Wayne Corbett | Spiroketone Acetyl-CoA Carboxylase Inhibitors |
PT2124933E (pt) | 2007-01-22 | 2013-01-07 | Pfizer Prod Inc | Sal tosilato de um composto terapêutico e composições farmacêuticas do mesmo |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
WO2009094528A1 (en) * | 2008-01-25 | 2009-07-30 | High Point Pharmaceuticals, Llc | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS |
US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
JP2011521940A (ja) | 2008-05-28 | 2011-07-28 | ファイザー・インク | ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
CN102149717B (zh) | 2008-08-28 | 2014-05-14 | 辉瑞大药厂 | 二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物 |
TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
GEP20156239B (en) | 2009-03-11 | 2015-01-26 | Pfizer | Benzofuranyl derivatives used as glucokinase inhibitors |
US20110319379A1 (en) | 2009-03-11 | 2011-12-29 | Corbett Jeffrey W | Substituted Indazole Amides And Their Use As Glucokinase Activators |
EP2408780A2 (en) | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicycloý3.3.1¨nonanes |
EP2427448A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
EP2427450A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
SG175995A1 (en) | 2009-06-05 | 2011-12-29 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
WO2013148748A1 (en) * | 2012-03-29 | 2013-10-03 | Francis Xavier Tavares | Lactam kinase inhibitors |
EP2841417A1 (en) * | 2012-04-26 | 2015-03-04 | Francis Xavier Tavares | Synthesis of lactams |
CA2900302C (en) * | 2013-02-19 | 2018-07-03 | Pfizer Inc. | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders |
WO2014144847A2 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
CN111772834B (zh) | 2014-03-21 | 2022-07-15 | 阿莱恩技术有限公司 | 具有弹性体的分段的正畸矫正器 |
TN2017000485A1 (en) * | 2015-06-17 | 2019-04-12 | Pfizer | Tricyclic compounds and their use as phosphodiesterase inhibitors |
DK3419979T3 (da) * | 2016-02-23 | 2020-03-23 | Pfizer | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazin-2-carboxamid-forbindelser |
-
2016
- 2016-06-09 TN TNP/2017/000485A patent/TN2017000485A1/en unknown
- 2016-06-09 CR CR20170572A patent/CR20170572A/es unknown
- 2016-06-09 ES ES16739563T patent/ES2832893T3/es active Active
- 2016-06-09 BR BR112017026191-0A patent/BR112017026191B1/pt active IP Right Grant
- 2016-06-09 AU AU2016280137A patent/AU2016280137B2/en active Active
- 2016-06-09 DK DK20193125.0T patent/DK3766885T3/da active
- 2016-06-09 PL PL16739563T patent/PL3310784T3/pl unknown
- 2016-06-09 CA CA2989456A patent/CA2989456C/en active Active
- 2016-06-09 PT PT201931250T patent/PT3766885T/pt unknown
- 2016-06-09 PL PL20193125.0T patent/PL3766885T3/pl unknown
- 2016-06-09 KR KR1020177036051A patent/KR20180004817A/ko active Application Filing
- 2016-06-09 CN CN201680034997.XA patent/CN107787322B/zh active Active
- 2016-06-09 US US15/736,942 patent/US11472805B2/en active Active
- 2016-06-09 DK DK16739563.1T patent/DK3310784T3/da active
- 2016-06-09 HU HUE16739563A patent/HUE051898T2/hu unknown
- 2016-06-09 EA EA201792425A patent/EA039714B1/ru unknown
- 2016-06-09 PT PT167395631T patent/PT3310784T/pt unknown
- 2016-06-09 HU HUE20193125A patent/HUE059372T2/hu unknown
- 2016-06-09 EP EP16739563.1A patent/EP3310784B1/en active Active
- 2016-06-09 CU CUP2017000153A patent/CU20170153A7/xx unknown
- 2016-06-09 PE PE2017002730A patent/PE20180478A1/es not_active Application Discontinuation
- 2016-06-09 SG SG10201912333PA patent/SG10201912333PA/en unknown
- 2016-06-09 EP EP20193125.0A patent/EP3766885B1/en active Active
- 2016-06-09 MX MX2017016149A patent/MX2017016149A/es unknown
- 2016-06-09 KR KR1020207014430A patent/KR102426986B1/ko active IP Right Grant
- 2016-06-09 WO PCT/IB2016/053398 patent/WO2016203347A1/en active Application Filing
- 2016-06-09 JP JP2017564677A patent/JP6827959B2/ja active Active
- 2016-06-09 ES ES20193125T patent/ES2924371T3/es active Active
- 2016-06-09 UA UAA201710872A patent/UA125334C2/uk unknown
- 2016-06-14 TW TW105118595A patent/TWI623538B/zh active
-
2017
- 2017-11-05 IL IL255444A patent/IL255444B/en active IP Right Grant
- 2017-12-11 PH PH12017502260A patent/PH12017502260A1/en unknown
- 2017-12-14 DO DO2017000297A patent/DOP2017000297A/es unknown
- 2017-12-19 CO CONC2017/0012994A patent/CO2017012994A2/es unknown
-
2018
- 2018-01-16 EC ECIEPI20183372A patent/ECSP18003372A/es unknown
- 2018-04-25 HK HK18105387.0A patent/HK1245790A1/zh unknown
- 2018-10-24 HK HK18113640.7A patent/HK1254661A1/zh unknown
-
2021
- 2021-01-15 AU AU2021200232A patent/AU2021200232A1/en not_active Abandoned
-
2022
- 2022-08-12 US US17/886,807 patent/US20230002386A1/en active Pending
- 2022-10-12 US US17/964,491 patent/US20230146535A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL247949A0 (en) | New histories of pyrazolopyrimidines and their use as malt1 inhibitors | |
IL251932B (en) | Benzylpropargyl ether as nitrification inhibitors | |
IL264258B (en) | Diazahetero-bicyclic substituted compounds and their use | |
SG11201708027XA (en) | Compounds and their use as bace1 inhibitors | |
HK1244486A1 (zh) | 三環dlk抑制劑及其用途 | |
IL251778A0 (en) | Novel pyrazolopyrimidine histories as nik inhibitors | |
HK1258849A1 (zh) | 三環pi3k抑制劑化合物及其使用方法 | |
HK1254661A1 (zh) | 三環化合物以及它們作為磷酸二酯酶抑制劑的用途 | |
HK1231468A1 (zh) | 三環化合物以及 抑制劑 | |
HK1250161B (zh) | 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途 | |
HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
PT3268356T (pt) | Compostos heterocíclicos e métodos para a sua utilização | |
GB201609580D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors | |
GB201514770D0 (en) | Compounds and their use | |
GB201513318D0 (en) | Novel compounds and their use |